Skip to content
TickerMagic

ANTHEM BIOSCIENCES LTD

ANTHEMNSEHealthcare
₹936.8
+22.45 (+2.46%) · EOD 2026-11-20

Our verdict

Sell

Quality (85/100) does the heavy lifting; valuation (1/100) is the drag.

ExpensiveHealth AOvervalued
Quality 85Momentum 77Value 1Trend 11The Spark ↓

Our fair value

Overvalued by 50%
₹468.4down 50.00%
Price ₹937Range ₹431 – ₹506

Buy-below (20% margin of safety): ₹374.72

The bottom line

TickerMagic rates ANTHEM BIOSCIENCES LTD a Sell, scoring 43/100 on our blended model. At ₹936.8 it trades above our blended DCF and relative-multiples fair value of ₹468.4, about 50% downside to that estimate — we read it as overvalued by 50%. On 76.2x trailing earnings it sits pricier than the Healthcare median of about 37.4x. It's trading right at its 52-week high of ₹958.15. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9. The average analyst target of ₹886.57 implies about 5% downside across 7 analysts. It clears 7 of 11 investability checks, with durability 85, valuation 1 and momentum 77 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹468.4down 50.00%
Overvalued by 50%
Price ₹936.8Range ₹430.93–₹505.87
DCF + relative blendmedium confidence

With a 20% margin of safety, our buy-below price is ₹374.72.

Analyst views

7 analysts7 buy · 0 hold · 0 sell
12-month consensus target₹886.57down 5.36%

1-year price

EOD · 2026-11-20
1D
up 2.46%
1W
down 0.18%
1M
up 15.87%
3M
up 5.13%
6M
up 19.29%
1Y
—

52-week range

-2.23% from the 52-week high.

Trend check
Above 50-DMA₹884Above 200-DMA₹785

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Sell43
A
Financial health 100/100
Altman Z 69.23 · Safe zone

Piotroski F-score 7/9 — quality of earnings & balance sheet.

Our scores

Durability85
Valuation1
Momentum77

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 7 of 11 checks
Each check screens one fundamentals, valuation or trend signal.
  • No data: ROE above 15%
  • Pass: Low debt (D/E < 0.5): 0.02x
  • Pass: Positive free cash flow
  • Fail: Revenue growth > 10%: -23%
  • Fail: Earnings growing: -13%
  • Pass: Net margin ≥ 10%: 28.7%
  • No data: Current ratio > 1.5
  • Fail: Below our fair value
  • Fail: Margin of safety ≥ 20%
  • Pass: Above 200-day average
  • Pass: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 69.23
  • Pass: Piotroski ≥ 7: 7/9

Quarterly results

Revenue · 2Q2026
₹418 Cr
Net profit
₹120 Cr
Margin
29%
3Q2025
4Q2025
1Q2026
2Q2026
Revenue Net profitLatest revenue QoQ -32%

Annual financials

Revenue · 2026
₹2,124 Cr
Net profit
₹592 Cr
Margin
28%
2025
2026
Revenue Net profitLatest revenue YoY +15%

Shareholding

  • Promoter84.2%
  • Institutions12.3%
  • Public & other3.5%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹43,246 Cr
P/E ratio
76.2
P/B ratio
14.21
EPS (TTM)
₹10.11
ROE
—
Debt / Equity
0.02x
Profit margin
28.7%
Free cash flow
₹633 Cr
52-week high
₹958.15
-2.23% from high
52-week low
₹590.86
Dividend yield
0.3%
Beta
—
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Lightly leveraged balance sheet.
  • Healthy profit margin (28.7%).
  • Trading near its 52-week high.
  • Financially solid — Altman Z 69.23.
  • High Piotroski quality score (7/9).

Bear case

Threats

  • Earnings contracting year on year.
  • Rich valuation versus sector peers.
  • Trades ~50% above our estimated fair value.

About ANTHEM BIOSCIENCES LTD

Anthem Biosciences Limited is a technology-focused contract research, development, and manufacturing organization operating through two segments: CRDMO services and Speciality Ingredients. The company provides end-to-end services across new chemical entity and new biological entity lifecycles, spanning target identification, concept stage, preclinical development, and manufacturing development batches.

ANTHEM BIOSCIENCES LTD — frequently asked questions

Is ANTHEM BIOSCIENCES LTD a buy, hold or sell?

TickerMagic currently rates ANTHEM BIOSCIENCES LTD (ANTHEM) a Sell, based on a blended score of 43/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is ANTHEM BIOSCIENCES LTD's fair value?

Our blended DCF and relative-valuation model estimates ANTHEM BIOSCIENCES LTD's fair value at about ₹468.4, versus a current price of ₹936.8 — roughly 50% downside. On that basis the stock looks overvalued by 50%.

Is ANTHEM BIOSCIENCES LTD financially healthy?

ANTHEM BIOSCIENCES LTD scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9.

How has ANTHEM BIOSCIENCES LTD's share price performed?

ANTHEM BIOSCIENCES LTD is up 5% over three months, and last traded at ₹936.8. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.